The initial public offering from Manipal Health Enterprises has been concluded, attracting significant institutional interest. The IPO was oversubscribed by 4.92 times, with most of the demand coming from the qualified institutional buyer (QIB) segment. Retail participation in the IPO fell far short of expectations and did not meet the full subscription quota expected of that market segment. The Grey Market Premium (GMP) reflects this divergence and when compared to its pre-IPO levels, the current value of the GMP heading into the 3 August commencement of the listing process is subdued.
What Is the Current GMP?
Manipal Health’s IPO currently has a GMP of around ₹6 per share. The upper end of the IPO price band was ₹590, indicating a listing price of approximately ₹596. The figures translate to a 1% implied gain in the listing price. However, the current Manipal Health IPO GMP is a far cry from the initial levels when the IPO commenced: it had hit around ₹25–35 at one point. The cooling that occurred as the IPO process progressed indicates a moderation of initial optimism among market participants. The sentiment being conveyed is that investors appear to have tapered their expectations along the way following a reassessment of the stock’s valuations and the offering’s size.
Why Is the Manipal Health IPO GMP Muted?
Several reasons have been adduced for the muted state of the Manipal Health IPO GMP.
1. Valuation Appears Stretched
As one of India’s leading private hospital chain operators, Manipal Health boasts a robust nationwide footprint and attractive long-term industry fundamentals. However, there is a consensus among financial analysts that the company’s IPO is overpriced compared to some of its hospital peers that are equally listed on the Indian stock markets. This is considered to leave too little room for near-term upside moves, especially in the immediate post-listing period. According to a Reuters valuation report, the stock issue has an 84.7X FY2026 earnings valuation, which means that a large portion of the expected price gain has already been captured in the IPO price.
2. Institutional Investors Are Driving Demand
The IPO was oversubscribed, but the demand profile was heavily tilted in favor of institutional investors. Retail participation was weak. The data shows that the Qualified Institutional Buyers (QIBs) segment registered an 8.25X subscription, while non-Institutional Investors (NIIs) had a 1.02X subscription weighting. Retail investors were only 0.93X subscribed. The data showcases institutional belief in the stock’s long-term potential.Â
3. Large IPO Size Limits Scarcity Premium
The IPO was sized at approximately ₹9,275 crore, making the Manipal Health IPO one of India’s largest healthcare public offerings in recent history. Historically, large-sized IPOs have resulted in lower GMPs, as the large number of shares produces an oversupply that limits any sharp jumps in listing-day prices.
4. Investors Are Looking Beyond Listing Gains
India’s healthcare sector has significant tailwinds. Healthcare spending is rising, along with demand for tertiary and quaternary care. Health insurance penetration is also increasing, along with growing consolidation in India’s hospital industry. This is why many institutional investors have a positive long-term outlook.
Investment Outlook
According to the IPO schedule, Manipal Health is scheduled for allotment on 3 August, ahead of its 5 August listing. What is the investment outlook for the stock?
- The company occupies a leading position in India’s private healthcare sector.
- It also boasts a highly diversified network of specialty hospitals.
- There is strong institutional support and belief in the stock’s long-term potential. Â
- The company stands to achieve significant debt reduction from the IPO’s proceeds, which strengthens the balance sheet and cuts down on debt-servicing and interest costs.
Like many other stocks, immediate listing gains may be limited, and we may even see a selloff due to the influx of sellers who initially obtained these holdings via private placement. Therefore, it is prudent to follow the institutional investors’ approach, which prioritizes long-term gains over immediate listing gains.
The long-term focus has to be on the company’s ability to deliver on its growth strategy, boost profitability, enhance its balance sheet, and appropriately monetize the demand factors in India’s healthcare industry.
For investors pursuing short-term listing gains, the GMP suggests limited near-term upside potential, warranting a cautious approach to near-term trading.